Abstract: An intravascular stent has a coating comprising a crosslinked amphiphilic polymer and a sparingly water soluble matrix metalloproteinase inhibitor (MMPI). Preferably the polymer is formed from 2-methacryloyloxy-2?-ethyltrimethylammonium phosphate inner salt, C4-18 alkyl methacrylate and reactive and/or crosslinking monomer and the MMPI is a hydroxamic acid, more preferably batimastat. Preclinical and clinical results are reported, showing good luminal areas and reduced intimal thickening.

Abstract: It is provided an intravascular stent comprising a metal body and a coating comprising a polymer and a restenosis inhibiting agent in which the restenosis inhibiting agent is a sparingly water soluble drug and the polymer in the coating is a cross-linked amphiphilic polymer, wherein the amphiphilic polymer comprises groups conferring hydrophobicity and groups conferring hydrophilicity.

Abstract: It is provided a method for producing a drug coated intravascular stent comprising coating a stent body with a cross-linkable amphiphilic polymer.

Abstract: A method of producing an intravascular stent has a coat comprising a crosslinked amphiphilic polymer and a sparingly water soluble matrix metalloproteinase inhibitor (MMPI). Preferably the polymer is formed from 2-methacryloyloxy-2?-ethyltrimethylammonium phosphate inner salt, C4-18 alkyl methacrylate and reactive and/or crosslinking monomer and the MMPI is a hydroxamic acid, more preferably batimastat. Preclinical and clinical results are reported, showing good luminal areas and reduced intimal thickening.

Abstract: An intravascular stent has a coat comprising a crosslinked amphiphilic polymer and a sparingly water soluble matrix metalloproteinase inhibitor (MMPI). Preferably the polymer is formed from 2-methacryloyloxy-2?-ethyltrimethylammonium phosphate inner salt, C4-18 alkyl methacrylate and reactive and/or crosslinking monomer and the MMPI is a hydroxamic acid, more preferably batimastat. Preclinical and clinical results are reported, showing good luminal areas and reduced intimal thickening.

Abstract: It is provided that a vascular stent having an amphiphilic polymer coating is loaded with a restenosis inhibiting agent which is sparingly soluble in water, whereby delayed release of the agent takes place after implantation of the stent.

Abstract: It is provided that a vascular stent having an amphiphilic polymer coating is loaded with a restenosis inhibiting agent which is sparingly soluble in water, whereby delayed release of the agent takes place after implantation of the stent.

Abstract: A vascular stent having an amphiphilic polymer coating is loaded with a restenosis inhibiting agent, which is sparingly soluble in water, whereby delayed release of the agent takes place after implantation of the stent.

Abstract: A method of producing an intravascular stent has a coat comprising a crosslinked amphiphilic polymer and a sparingly water soluble matrix metalloproteinase inhibitor (MMPI). Preferably the polymer is formed from 2-methacryloyloxy-2?-ethyltrimethylammonium phosphate inner salt, C4-18 alkyl methacrylate and reactive and/or crosslinking monomer and the MMPI is a hydroxamic acid, more preferably batimastat. Preclinical and clinical results are reported, showing good luminal areas and reduced intimal thickening.

Abstract: An intravascular stent has a coat comprising a crosslinked amphiphilic polymer and a sparingly water soluble matrix metalloproteinase inhibitor (MMPI). Preferably the polymer is formed from 2-methacryloyloxy-2?-ethyltrimethylammonium phosphate inner salt, C4-18 alkyl methacrylate and reactive and/or crosslinking monomer and the MMPI is a hydroxamic acid, more preferably batimastat. Preclinical and clinical results are reported, showing good luminal areas and reduced intimal thickening.

Abstract: An intravascular stent has a coat comprising a crosslinked amphiphilic polymer and a sparingly water soluble matrix metalloproteinase inhibitor (MMPI). Preferably the polymer is formed from 2-methacryloyloxy-2?-ethyltrimethylammonium phosphate inner salt, C4-18 alkyl methacrylate and reactive and/or crosslinking monomer and the MMPI is a hydroxamic acid, more preferably batimastat. Preclinical and clinical results are reported, showing good luminal areas and reduced intimal thickening.

Abstract: A tampon for feminine hygiene or medical purposes comprising a nonwoven cover having at least one, outwardly directed, smooth surface and substantially enclosing a liquid absorbing core wherein the nonwoven cover comprises at least partly thermoplastic, heat-sealable fibers and pressed to the final shape of the tampon. Before the tampon blank is covered with the nonwoven covering web, said web was subject to the use of heat and pressure during the manufacturing of the tampon as to smooth out at least the outer surface of the nonwoven covering web, whilst maintaining the structure of the nonwoven covering web and the absorbency of the tampon. Thereby, it is achieved that the tampon can also be more easily and more comfortably introduced into and withdrawn from a body cavity before and after the days of stronger menstruation or at the occurance of only less vaginal exudation as garment protection.

Abstract: An intravascular stent has a coat comprising a crosslinked amphiphilic polymer and a sparingly water soluble matrix metalloproteinase inhibitor (MMPI). Preferably the polymer is formed from 2-methacryloyloxy-2′-ethyltrimethylammonium phosphate inner salt, C4-18 alkyl methacrylate and reactive and/or crosslinking monomer and the MMPI is a hydroxamic acid, more preferably batimastat. Preclinical and clinical results are reported, showing good luminal areas and reduced intimal thickening.

Abstract: A tampon for feminine hygiene or medical purposes comprising a nonwoven cover having at least one, outwardly directed, smooth surface and substantially enclosing a liquid absorbing core wherein the nonwoven cover comprises at least partly thermoplastic, heat-sealable fibers and pressed to the final shape of the tampon. Before the tampon blank is covered with the nonwoven covering web, said web was subject to the use of heat and pressure during the manufacturing of the tampon as to smooth out at least the outer surface of the nonwoven covering web, whilst maintaining the structure of the nonwoven covering web and the absorbency of the tampon. Thereby, it is achieved that the tampon can also be more easily and more comfortably introduced into and withdrawn from a body cavity before and after the days of stronger menstruation or at the occurance of only less vaginal exudation as garment protection.

Abstract: A tampon for feminine hygiene or medical purposes comprising a nonwoven cover having at least one, outwardly directed, smooth surface and substantially enclosing a liquid absorbing core wherein the nonwoven cover comprises at least partly thermoplastic, heat-sealable fibers and pressed to the final shape of the tampon. Before the tampon blank is covered with the nonwoven covering web, said web was subject to the use of heat and pressure during the manufacturing of the tampon as to smooth out at least the outer surface of the nonwoven covering web, whilst maintaining the structure of the nonwoven covering web and the absorbency of the tampon. Thereby, it is achieved that the tampon can also be more easily and more comfortably introduced into and withdrawn from a body cavity before and after the days of stronger menstruation or at the occurance of only less vaginal exudation as garment protection.